Inflammatory Skin Disease Summit 2014
Transcription
Inflammatory Skin Disease Summit 2014
November 19 – 21, 2014 Inflammatory Skin Disease Summit 2014 The Translational Revolution Austrian Academy of Sciences Dr. Ignaz Seipel-Platz 2, Vienna, Austria FINAL PROGRAMME ORGANISED BY: Austrian Academy of Sciences www.oeaw.ac.at/isds2014 II Neu bei Psoriasis-Arthritis Prix Galien USA for Best Biotechnology Product Symptomkontrolle bis in die Fingerspitzen 2 nach zwei Initialdosen subkutan alle 12 Wochen1 starke, anhaltende Wirkung in der Psoriasis-Arthritis2 hemmt gezielt die inflammatorischen Zytokine Interleukin-12 und -23 1 1. Fachinformation Stelara®, 20.03.20147 2. McInnes I. et al. Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial. Lancet 2013 Jun 12. doi: 10.1016/S0140-6736(13) 60594-2 FACHKURZINFORMATION STELARA® Bezeichnung des Arzneimittels: STELARA® 45 mg bzw. 90 mg Injektionslösung in einer Fertigspritze. Qualitative und quantitative Zusammensetzung: Jede Fertigspritze für den Einmalgebrauch enthält 45 mg Ustekinumab in 0,5 ml bzw. 90 mg Ustekinumab in 1 ml. Ustekinumab ist ein rein humaner monoklonaler IgG1κ-Antikörper gegen Interleukin (IL)-12/23, der unter Verwendung rekombinanter DNA-Technologie in einer murinen Myelomzelllinie produziert wird. Sonstige Bestandteile: Sucrose, Histidin, Histidinhydrochlorid-Monohydrat, Polysorbat 80, Wasser für Injektionszwecke. Anwendungsgebiete: Plaque-Psoriasis: STELARA® ist für die Behandlung erwachsener Patienten mit mittelschwerer bis schwerer Plaque- Psoriasis indiziert, bei denen andere systemische Therapien einschließlich Ciclosporin, Methotrexat (MTX) oder PUVA (Psoralen und Ultraviolett A) nicht angesprochen haben, kontraindiziert sind oder nicht vertragen wurden. Psoriatische Arthritis (PsA): STELARA® ist allein oder in Kombination mit MTX für die Behandlung der aktiven psoriatischen Arthritis bei erwachsenen Patienten indiziert, wenn das Ansprechen auf eine vorherige Therapie mit nicht-biologischen krankheitsmodifizierenden Antirheumatika (DMARDs) unzureichend gewesen ist. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. Klinisch relevante, aktive Infektion (z. B. aktive Tuberkulose). Inhaber der Zulassung: Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgien. Verschreibungspflicht/Apothekenpflicht: Rezept- und apothekenpflichtig. ATCCode: L04AC05. Weitere Angaben zu Warnhinweisen und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkungen mit anderen Arzneimitteln und sonstigen Wechselwirkungen, Schwangerschaft und Stillzeit sowie Nebenwirkungen entnehmen Sie bitte der veröffentlichten Fachinformation. EAP 109076 PHAT/STE/1213/0004 Inflammatory Skin Disease Summit 2014 Table of Contents Table of Contents WELCOMING WORDS – ORGANISING COMMITTEE 3 GENERAL INFORMATION 5 REGISTRATION 10 NETWORKING EVENTS 11 SCIENTIFIC PROGRAMME INFORMATION 12 SCIENTIFIC PROGRAMME 15 ACCEPTED ABSTRACTS 19 COMMERCIAL EXHIBITION/SPONSORSHIP 42 INDUSTRY-SUPPORTED SESSIONS 44 VIENNA, November 19 – 21, 2014 1 dedicated to innovation exceptionalscience gh ro u th cr ea tin g ne w po ss ib ili tie MedImmune leads a movement that demands more out of medicine. With one of the largest and most robust pipelines in the industry, we pioneer the future of science — creating advancements in biotechnology that have a true impact on health. sc ie nc e. s 2 www.medimmune.com © 2014 MedImmune. All rights reserved. LOOK INSIDE THE CELL FOR A NEW PERSPECTIVE DISCOVER THE ROLE OF PDE4 IN PSORIASIS AND PSORIATIC ARTHRITIS PDE4 promotes the dysregulation of pro- and anti-inflammatory mediators thought to occur in inflammatory disease1,2 and is present in key inflammatory cells implicated in psoriasis and psoriatic arthritis.2-4 PDE4, phosphodiesterase-4; AMP, adenosine monophosphate; cAMP, cyclic AMP. References: 1. Houslay MD, et al. Keynote review: phosphodiesterase-4 as a therapeutic target. Drug Discov Today. 2005;10(22):1503–1519. 2. Press NJ and Banner KH. PDE4 inhibitors – a review of the current field. In: Lawton G, Witty DR, eds. Progress in Medicinal Chemistry. Amsterdam, The Netherlands: Elsevier; 2009:37–74. 3. Lowes MA, et al. Pathogenesis and therapy of psoriasis. Nature. 2007;445(7130):866–873. 4. Veale DJ, et al. Immunopathology of psoriasis and psoriatic Ann Rheum Dis. 2005;64(suppl 2):ii26–ii29. Inflammatory Skinarthritis. Disease Summit 2014 © 2014 Celgene Corporation Date of Preparation October 2014 AP/1037/08102014 PDE4 AMP cAMP Welcoming Words – Organising Committee Welcoming Words – Organising Committee Dear participants, it is an honor and our great pleasure to welcome you to the “Inflammatory Skin Disease Summit 2014 – The Translational Revolution”! In the past decade, we have experienced a veritable breakthrough in the management of inflammatory skin diseases, which were previously lacking satisfactory treatments. This revolution is particularly evident with the introduction of novel targeted therapies for key inflammatory skin diseases such as psoriasis, atopic dermatitis and few other inflammatory conditions. This translational revolution stems from a growing knowledge of pathogenic pathways, and the advent of new technologies that are directly applicable to human biologic substrates. These ultimately led to the development of narrow therapeutics, and to their testing in clinical trials, further amplifying our current disease understanding. Under the patronage of the Austrian Academy of Sciences, we have taken the initiative to organise a symposium entitled „Inflammatory Skin Disease Summit: The Translational Revolution“ that directly addresses and describes this new development. We aim to deliver an outstanding meeting to our participants including plenary lectures given by world leaders in their fields, poster sessions, oral presentations of selected abstracts and, most importantly, a vivid discussion in the lecture hall, in front of the many posters, and during our social events. We want to thank all participants who have decided to join us for what we hope will be a scientifically most stimulating event, all invited speakers and poster presenters for sharing their work with us, our generous sponsors, and all the helping hands making this meeting possible. We very much hope that you will enjoy this symposium in the historic center of Vienna. With kind regards, James G. Krueger, M.D., Ph.D. Emma Guttman-Yassky, M.D., Ph.D. Georg Stingl, M.D. Patrick M. Brunner, M.D. VIENNA, November 19 – 21, 2014 3 Maurer M, et al., Hautarzt 2013 . 64:638-643 vereinfachte Darstellung der Urticaria Guidelines: 1-fach Dosierung eines H1-AH, danach bis zu 4-fach Dosierung, danach Omalizumab als eine von 3 Alternativen (Omalizumab, Cyclosporin A, Montelukast) Inflammatory Skin Disease Summit 2014 Datum der Erstellung: 9/2014 | AT1405204277 * 1 Prescribing Information see page 45 ZEIT FÜR VERÄNDERUNG BEI CHRONISCH SPONTANER URTIKARIA / csU 4 Welcoming Words – Organising Committee 1— 4 — OMA 1,* General Information General Information ORGANISING COMMITTEE James G. Krueger, M.D., Ph.D. Director, Milstein Medical Research Program Senior Attending Physician D. Martin Carter Professor in Clinical Investigation Laboratory of Investigative Dermatology The Rockefeller University, N.Y., USA Emma Guttman-Yassky, M.D., Ph.D. Assoc. Professor of Dermatology & Immunology Director, Center for Excellence in Eczema and Occupational/Contact Dermatitis Director, Laboratory of Inflammatory Skin Diseases Icahn School of Medicine at Mount Sinai Hospital, N.Y., USA Georg Stingl, M.D. Professor and Chairman Div. of Immunology, Allergy and Infectious Diseases Dpt. of Dermatology Medical University of Vienna, Austria Patrick M. Brunner, M.D. Div. of Immunology, Allergy and Infectious Diseases Dpt. of Dermatology Medical University of Vienna, Austria VIENNA, November 19 – 21, 2014 5 6 General Information PROFESSIONAL CONGRESS ORGANISER, SCIENTIFIC SECRETARIAT & ACCOMMODATION BOOKING Mondial Congress & Events Operngasse 20b, 1040 Vienna, Austria Phone: +43 1 58804-0 Fax: +43 1 58804 185 E-mail: [email protected] COMMERCIAL EXHIBITION / SPONSORSHIP MAW-Medizinische Ausstellungs- und Werbegesellschaft Mrs. Ingrid Winkler Mag. Michael Schneider Freyung 6/3/3, 1010 Vienna, Austria Phone: +43 1 536 63 33 or +43 1 536 63 82 Fax: +43 1 536 63 61 E-mail: [email protected] or [email protected] CONGRESS VENUE Austrian Academy of Sciences Dr. Ignaz Seipel-Platz 2 1010 Vienna, Austria HOW TO GET TO THE CONGRESS VENUE USING PUBLIC TRANSPORTATION The closest underground stations are: U1/U3 Stephansplatz Inflammatory Skin Disease Summit 2014 General Information U3 Stubentor U1/U4 Schwedenplatz VIENNA, November 19 – 21, 2014 7 General Information A treasure trove of fascinating and richly illustrated information History of Allergy Chemical Immunology and Allergy Editors: J. Ring, K. Blaser, M. Capron, J.A. Denburg, S.T. Holgate, G. Marone, H. Saito Vol. 100 History of Allergy Editors Edited by K.-C. Bergmann J. Ring Karl-Christian Bergmann Berlin Johannes Ring Munich O 6 7 4 5 1 8 Chromone This book presents a detailed and varied historical overview of the field of allergology. Special highlights are the personal reflections of and interviews with a number of pioneers in allergy, including F. Austen, J. Bienenstock, K. Blaser, A. de Weck, A.W. Frankland, K. Ishizaka, and many more. Chemical Immunology and Allergy, Vol. 100 History of Allergy Editors: Bergmann K.-C. (Berlin), Ring J. (Munich) XX + 426 p., 257 fig., 127 in color, 20 tab., hard cover, 2014 ISBN 978–3–318–02194–3 e-ISBN 978–3–318–02195–0 CHF 115.00 / EUR 96.00 / USD 135.00 (hard cover) 3 2 O Section Titles • Allergy through 20 Centuries • Most Common Allergic Diseases: Historical Reflections in Understanding • Mechanisms of Allergy: Important Discoveries • Detection of Environmental Influences and Allergens • Progress in Allergy Management • Pioneers of Allergy: Personal Reflections • Allergy Societies and Collections • Online Supplementary Material View free sample chapters and order your copy at www.karger.com/chial S. Karger AG, P.O. Box, 4009 Basel (Switzerland) f: +41 61 306 12 34, e: [email protected] Inflammatory Skin Disease Summit 2014 KI 14253_A5 8 General Information CLOAKROOM A cloakroom and luggage storage facilities will be available next to the Registration Counters on the ground floor. SMOKING AREA Thank you for not smoking inside the congress venue. Smoking areas can be found outside the main entrance. WIFI Free WIFI is available. Please ask at the registration desk for username and password. VENUE Ground floor First floor VIENNA, November 19 – 21, 2014 9 10 Registration Registration The registration area is located on the ground floor. The Mondial Congress & Events team as well as the congress hostesses will be pleased to help you with any inquiries. Please do not hesitate to approach the team members if there is anything they can do to make your stay more enjoyable. REGISTRATION HOURS Wednesday, November 19, 2014 Thursday, November 20, 2014 Friday, November 21, 2014 10:00 – 19:00 07:30 – 19:00 08:00 – 11:00 ONSITE REGISTRATION FEES Delegate EUR 250,00 Student/Trainee/Fellow EUR 150,00 The participants’ registration fee includes: —— —— —— —— —— —— —— —— Admission to all scientific sessions Admission to scientic poster area and commercial exhibition Congress materials (congress bag, final programme, badge, abstract book) Certificate of attendance Coffee breaks Opening Ceremony & Welcome Reception on Wednesday, November 19, 2014 Reception on Thursday, November 20, 2014 from 18:30 – 20:00 Industry supported sessions PAYMENT DETAILS Please note that all onsite payments need to be made in cash or by credit card (Visa, Mastercard, American Express, Diners Club will be accepted) in EURO only. We cannot accept traveller’s cheques, other credit cards, Euro cheques or other currencies. Inflammatory Skin Disease Summit 2014 Networking Events Networking Events WELCOME RECEPTION & POSTER VIEWING Wednesday, November 19, 2014, 18:30 – 21:00 Location: Exhibition & Poster Area – Ground Floor Enjoy the Welcome Reception in the Exhibition & Poster Area with drinks and a “flying buffet”. POSTER VIEWING & DRINKS Thursday, November 20, 2014, 18:30 – 20:00 Location: Exhibition & Poster Area – Ground Floor During poster viewing, drinks will be offered. LUNCH Lunchboxes will be provided by Regeneron and Sanofi on Thursday, November 20, 2014 at 12:00 on the first floor. COFFEE BREAKS Coffee, tea, juice, water, fruit and pastries & cake will be offered during coffee breaks in the Exhibition Area on the ground floor. Coffee breaks are scheduled as follows: —— —— —— —— Wednesday, November 19, 2014 Thursday, November 20, 2014 Thursday, November 20, 2014 Friday, November 21, 2014 16:20 – 17:00 10:00 – 10:30 15:30 – 17:00 10:00 – 10:30 sponsored by Pfizer VIENNA, November 19 – 21, 2014 11 12 Scientific Programme Information Scientific Programme Information OPENING HOURS – SPEAKERS’ PREVIEW CENTER The Speakers‘ Preview Center is located on the first floor in room “Johannessaal”. The opening hours are as follows: Wednesday, November 19, 2014 Thursday, November 20, 2014 Friday, November 21, 2014 12:00 – 19:00 07:30 – 19:00 08:00 – 10:30 PRESENTATION GUIDELINES 1. Please locate the session room in due time. Please be at the session room at least 15 minutes prior to the start of the session. 2. Speakers should deliver and view/check their PowerPoint presentations at the Speakers‘ Preview Center (room „Johannessaal“) at least 2 hours prior to the start of the respective session. For sessions starting at 08:30, the PowerPoint presentation should be delivered the previous day. In order to avoid any delays, speakers are kindly requested to hand in their PowerPoint presentations on USB. If you bring your own laptop, the presentation will be transferred onsite in the Preview Centre. Please do not take PowerPoint presentations directly to the technical assistant in the Session rooms. CHAIRPERSON GUIDELINES Please locate your session room in due time. Please be at the session room at least 15 minutes prior to the start of the session. We may remind you that speakers need to strictly stick to the time schedule. POSTERS The poster area is located on the ground floor. Each poster will be displayed for the entire duration of the congress. Posters have to be mounted on Wednesday, November 19 between 11:00 and 15:00. Please attach the poster to the board with the corresponding poster placement number and remove it on Friday, November 21, 2014 until 10:30. Otherwise our staff will remove it. Inflammatory Skin Disease Summit 2014 Scientific Programme Information ABSTRACT BOOK A printed abstract book will be provided in your congress bag. Moreover, the abstracts will be published in the Journal “Experimental Dermatology”. TRAVEL FELLOWSHIPS Travel Fellowships need to be picked up at the registration desk on Thursday, November 20, 2014 from 10:00 – 12:00. INVITED SPEAKERS Masayuki Amagai Robert Bissonnette Anne Bowcock Angela M. Christiano Alexander Enk Kilian Eyerich Lars French Richard Gallo Michel Gilliet Emma Guttman-Yassky Muzlifah Haniffa Thomas Jung James G. Krueger Thomas S. Kupper Thomas Luger Marcus Maurer Frank Nestle Jean-Francois Nicolas Kristian Reich Martin Röcken Martin Steinhoff Georg Stingl Peter van de Kerkhof Wolfgang Weninger Tokyo, Japan Montreal, Canada London, United Kingdom New York City, NY, USA Heidelberg, Germany Munich, Germany Zurich, Switzerland San Diego, CA, USA Lausanne, Switzerland New York City, NY, USA Newcastle, United Kingdom Zurich, Switzerland New York City, NY, USA Boston, MA, USA Münster, Germany Berlin, Germany London, United Kingdom Lyon, France Hamburg, Germany Tübingen, Germany Dublin, Ireland Vienna, Austria Amsterdam, The Netherlands Sydney, Australia VIENNA, November 19 – 21, 2014 13 14 Scientific Programme Information SESSION CHAIRS Patrick Brunner Enno Christophers Kevin Cooper Dean Mann Stefanie Eyerich Mayumi Fujita Emma Guttman-Yassky Conrad Hauser Emmilia Hodak Sarolta Karpati Christine Neumann Graham Ogg Luis Puig Nikolaus Romani Annika Scheynius Erwin Tschachler Rudolf Valenta Klaus Wolff Vienna, Austria Kiel, Germany Cleveland, OH, USA Baltimore, MD, USA Munich, Germany Aurora, CO, USA New York City, NY, USA Geneva, Switzerland Petah Tiqva, Israel Budapest, Hungary Cologne, Germany Oxford, United Kingdom Barcelona, Spain Innsbruck, Austria Stockholm, Sweden Vienna, Austria Vienna, Austria Vienna, Austria Transforming the language of life into vital medicines At Amgen, we believe that the answers to medicine's most pressing questions are written in the language of our DNA. As pioneers in biotechnology, we use our deep understanding of that language to create vital medicines that address the unmet needs of patients fighting serious illness – to dramatically improve their lives. For more information about Amgen, our pioneering science and our vital medicines, visit www.amgen.com. Amgen is proud to support the Inflammatory Skin Disease Summit 2014 Amgen Europe GmbH, Dammstrasse 23, CH-6301 Zug Inflammatory Skin Disease Summit 2014 ©2014 Amgen Inc. All rights reserved. AMG-IHQ-AMG-613-2014-October-NP/AMG-AUT-AMG-801-2014-October-NP Scientific Programme Scientific Programme WEDNESDAY, NOVEMBER 19, 2014 Clinical afternoon – Trailblazing the clinical trial landscape Chairs: Enno Christophers (Kiel, Germany), Klaus Wolff (Vienna, Austria) (Kindly supported by Boehringer Ingelheim) 15.00 – 15.20 Upcoming trials in psoriasis Peter van de Kerkhof (Nijmegen, The Netherlands) 15.20 – 15.40 Can treatment of inflammatory skin diseases improve systemic inflammation? Robert Bissonnette (Montreal, Canada) 15.40 – 16.00 IgE-specific immune-absorption in adult patients with severe atopic dermatitis Kristian Reich (Hamburg, Germany) 16.00 – 16.20 Rosacea – Pathogenesis and new treatments Martin Steinhoff (Dublin, Ireland) 16:20 – 17:00 Coffee Break Opening Chairs: Emma Guttman-Yassky (New York City, NY), Patrick Brunner (Vienna, Austria) 17.00 – 17.30 Opening & Welcome Georg Stingl (Vienna, Austria) 17.30 – 17.45 Setting the stage Georg Stingl (Vienna, Austria) 17.45-18.15 Skin Associated Lymphoid Tissue Revisited Thomas S. Kupper (Boston, MA) 18.15-18.45 Inflammatory skin diseases – The technological revolution James G. Krueger (New York City, NY) 18.45-21:00 Reception and poster viewing VIENNA, November 19 – 21, 2014 15 16 Scientific Programme THURSDAY, NOVEMBER 20, 2014 Morning lectures: Cellular and molecular circuits in cutaneous inflammation Chairs: Nikolaus Romani (Innsbruck, Austria), Erwin Tschachler (Vienna, Austria) 08:30 – 09.00 Mediators of inflammation Thomas Luger (Münster, Germany) 09.00 – 09:30 Innate immunity and dendritic cells Michel Gilliet (Lausanne, Switzerland) 09:30 – 10:00 AMPs and the microbiome Richard Gallo (San Diego, CA) 10.00 – 10:30 Coffee break Chairs: Dean Mann (Baltimore, MD), Graham Ogg (Oxford, United Kingdom) 10:30 – 11.00 The inflammasome and autoinflammation Lars French (Zurich, Switzerland) 11.00 – 11:30 Antigen presentation in the skin Muzlifah Haniffa (Newcastle, United Kingdom) 11:30 – 12.00 Lymphocytes – The family is growing Wolfgang Weninger (Sydney, Australia) 12:00 – 14.00 Sponsored lunch symposium (Regeneron and Sanofi) 14.00 – 14.30 Oral presentations from selected abstracts Chairs: Mayumi Fujita (Aurora, CO); Emmilia Hodak (Petah Tiqva, Israel) P001 Rosacea is more than skin deep: Patients have higher odds of having chronic systemic diseases in a skin severity-dependent manner B. M. Rainer1, A. H. Fischer1, D. Luz Felipe da Silva1, S. Kang1, A. L. Chien1 1Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA Inflammatory Skin Disease Summit 2014 Scientific Programme P002 Targeting the IFN-γ-CXCL10 axis in keratinocytes to develop novel treatments for vitiligo J. M. Richmond1, K. Essien1, S. Currimbhoy2, A. Pandya2, D. Bangari3, M. Youd3, J. R. Groom4, A. D. Luster5, J. E. Harris1 1Division of Dermatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA 2Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX, USA 3Genzyme, a Sanofi Corporation, Framingham, MA, USA 4 Walter and Eliza Hall Institute of Medical Research & University of Melbourne, Melbourne, Australia 5 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA P003 Epidermal Tissue-Resident Memory T cells Form a Localised Memory in Clinically Healed Psoriasis S. S. H. Cheuk1, M. Ståhle1, L. Eidsmo1 1Dermatology and Venerology Unit / Department of Medicine / Solna / Karolinska Institutet, Stockholm, Sweden Afternoon lectures: Mechanisms of disease – Autoimmunity Chairs: Stefanie Eyerich (Munich, Germany), Annika Scheynius (Stockholm, Sweden) 14.30 – 15.00 Therapeutic polarization of the immune response Martin Röcken (Tübingen, Germany) 15.00 – 15.30 IVIG in dermatology Alexander Enk (Heidelberg, Germany) 15.30 – 17.00 Sponsored symposium (Pfizer) Chairs: Sarolta Karpati (Budapest, Hungary), Kevin Cooper (Cleveland, OH) 17.00 – 17.30 Chronic urticaria Marcus Maurer (Berlin, Germany) 17.30 – 18.00 Towards antigen-specific immune suppression in pemphigus Masayuki Amagai (Tokyo, Japan) 18.00 – 18.30 Alopecia areata – Pathogenesis and possible treatments Angela Christiano (New York City, NY) 18.30 – 20:00 Drinks and poster viewing VIENNA, November 19 – 21, 2014 17 18 Scientific Programme FRIDAY, NOVEMBER 21, 2014 Morning lectures: Mechanisms of disease – The complex interactions between the genetic, immune and barrier interphase in eczema and psoriasis Chairs: Rudolf Valenta (Vienna, Austria), Luis Puig (Barcelona, Spain) 08.30 – 09.00 Systems biology, biomarkers, and predictive medicine Frank O. Nestle (London, United Kingdom) 09.00 – 09.30 The genetics and epigenetics of psoriasis and atopic dermatitis Anne Bowcock (London, United Kingdom) 09.30 – 10.00 Irritant and allergic contact dermatitis and drug allergy – Pathogenesis and therapeutic implications Jean-Francois Nicolas (Lyon, France) 10.00 – 10.30 Coffee break Chairs: Christine Neumann (Cologne, Germany), Conrad Hauser (Geneva, Switzerland) 10.30 – 11.00 Cross talk between T-cell subsets and implications for inflammatory skin diseases Kilian Eyerich (Munich, Germany) 11.00 – 11.30 Evolving concepts in atopic dermatitis and implications for targeted therapeutics Emma Guttman-Yassky (New York City, NY) 11.30 – 12.00 From target discovery to therapeutic development Thomas Jung (Zurich, Switzerland) Inflammatory Skin Disease Summit 2014 Accepted Abstracts Accepted Abstracts All abstracts will be published in the Journal “Experimental Dermatology” and a printed abstract book will be provided in your congress bag. P001 Rosacea is more than skin deep: Patients have higher odds of having chronic systemic diseases in a skin severity-dependent manner B. M. Rainer1, A. H. Fischer1, D. Luz Felipe da Silva1, S. Kang1, A. L. Chien1 1Department of Dermatology, Johns Hopkins School of Medicine, Baltimore, Maryland, USA P002 Targeting the IFN-γ-CXCL10 axis in keratinocytes to develop novel treatments for vitiligo J. M. Richmond1, K. Essien1, S. Currimbhoy2, A. Pandya2, D. Bangari3, M. Youd3, J. R. Groom4, A. D. Luster5, J. E. Harris1 1Division of Dermatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA, USA 2Department of Dermatology, University of Texas Southwestern Medical Center, Dallas, TX 3Genzyme, a Sanofi Corporation, Framingham, MA, USA 4 Walter and Eliza Hall Institute of Medical Research & University of Melbourne, Melbourne, Australia 5 Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA P003 Epidermal Tissue-Resident Memory T cells Form a Localised Memory in Clinically Healed Psoriasis S. S. H. Cheuk1, M. Ståhle1, L. Eidsmo1 1Dermatology and Venerology Unit / Department of Medicine / Solna / Karolinska Institutet, Stockholm, Sweden P004 IL-17A induces inflammation-associated gene products in blood monocytes and treatment with ixekizumab reduces their expression in psoriasis patient blood C. Wang1, M. Suarez-Farinas1, K. Nograles1, C. Abrantes Mimoso1, D. Shrom2, E. Dow2, M. P. Heffernan2, R. W. Hoffman2, J. G. Krueger1 1Rockefeller University, New York, USA 2Eli Lilly, Indianapolis, USA VIENNA, November 19 – 21, 2014 19 20 Accepted Abstracts P005 Specific roles for dendritic cell subsets during initiation and progression of psoriasis E. Glitzner1, A. Korosec1, P. M. Brunner2, B. Drobits1, N. Amberg1, H. B. Schonthaler3, T. Kopp2, E. F. Wagner3, G. Stingl2, M. Holcmann1, M. Sibilia1 1Institute of Cancer Research, Department of Medicine I, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria 2Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria. 3BBVA Foundation–CNIO Cancer Cell Biology Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain P006 Successful use of ustekinumab therapy in refractory severe atopic dermatitis Y. Mansouri1, A. Shroff1, E. Guttman1 1Icahn School of Medicine at Mount Sinai, New York, USA P007 Low dose inhalation of Interleukin-2 (IL-2) bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients C. Posch1,2, F. Weihsengruber1, K, Bartsch1, V. Feichtenschlager1, M. Sanlorenzo2,3, I. Vujic1, B. Monshi1, S. Ortiz-Urda2, K. Rappersberger1 1The Rudolfstiftung Hospital, Academic Teaching Hospital, Medical University Vienna, Department of Dermatology, Vienna, Austria 2University of California San Francisco, Department for Dermatology, Mt. Zion Cancer Research Center, San Francisco, USA 3Department of Medical Sciences, Section of Dermatology, University of Turin, Turin, Italy P008 Hyper IgE (Job Syndrome) with abdominal aortic aneurysm and leucoma corneae B. Kotevska1, Z. Demerdzhieva1, R. Darlenski1, N. Tsankov1 1Tokuda Hospital, Sofia, Bulgaria P009 Identification of TSLP-responsive dermal DC in murine skin hypersensitivity models S. Ochiai1, B. Roediger2, E. Shklovskaya2, B. Fazekas de St Groth2, H. Yamane3, W. Weninger2, G. Le Gros1, F. Ronchese1 1Malaghan Institute of Medical Research, Wellington, New Zealand 2Centenary Institute, Sydney NSW, Australia 3National Institutes of Health, Bethesda, MD, USA Inflammatory Skin Disease Summit 2014 Accepted Abstracts P010 Cryopyrin-associated Periodic Syndrome Caused by a Novel Mutation in the NLRP3 Gene V. Mateeva1, M. Kadurina1 1Department of Dermatovenerology and Allergology; Military Medical Academy, Sofia, Bulgaria P011 Comparison of negative immune regulators between a prototypic delayed-type hypersensitivity reaction induced by diphencyprone and psoriasis vulgaris: potential insights into chronic inflammation N. Gulati1, M. Suárez-Fariñas1, J. Correa da Rosa1, J. G. Krueger1 1The Rockefeller University, New York, USA P012 Skin response to a carcinogen involves the xenobiotic receptor pregnane X receptor A. Elentner1, D. Ortner1, F. Sparber1, S. Ebner2, B. Del Frari3, F. J. Gonzalez4, P. M. Fernández-Salguero5, M. Schmuth1, S. Dubrac1 1Department of Dermatology and Venereology, Innsbruck Medical University, Innsbruck, Austria. 2VTT Daniel Swarovski Laboratory, Department of Surgery, Innsbruck Medical University, Innsbruck, Austria 3Department of Plastic, Reconstructive and Esthetic Surgery, Innsbruck Medical University, Innsbruck, Austria 4 Laboratory of Metabolism, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA 5 Department of Biochemistry, Molecular Biology and Genetics, Faculty of Sciences, University of Extremadura, Badajoz, Spain P013 Dissection of Inflammatory Pathways and Molecular Trajectories of Multiple Therapeutics C. Russel1, R. Hu1, J. Bigler1, M. Boedigheimer2, B. Sullivan2, G. Kricorian2, P. Klekotka2, J. Chung2, K. Newhall1, D. Martin1 1Amgen Inc., Seattle WA, USA 2Amgen Inc., Thousand Oaks, CA, USA VIENNA, November 19 – 21, 2014 21 Regeneron and Sanofi: 22 Accepted Abstracts A scientific collaboration focused on the disco fully human monoclonal antibodies. An investigational drug is in development fully-human monoclonal antibody specific moderate-to-severe atopic dermatitis. 3 Phase 2b: completed 3 Phase 3 clinical studies: on-g Regene the Inf The investigational agent described above is current been evaluated for approval by any regulatory author © 2014, Regeneron Pharmaceuticals, Inc. and Sanofi. ILF-0224/SAGLB.DUP.14.10.0326 Inflammatory Skin Disease Summit 2014 Accepted Abstracts 23 overy and development of targeted as a subcutaneously-administered, c for the IL-4Rα subunit for uncontrolled going CLINICAL TRIAL PROGRAM IN ATOPIC DERMATITIS eron and Sanofi are proud sponsors of flammatory Skin Disease Summit 2014 tly under clinical development, and the safety and efficacy have not rity. All rights reserved 10/2014 VIENNA, November 19 – 21, 2014 24 Accepted Abstracts P014 Differential DNA methylation and microRNA expression in skin-homing CLA+ T cells of atopic eczema patients A. Scheynius1, N. Acevedo1,2, S. Bruhn1, A. Andersson1, G. Wikberg3, L. Lundeberg3, C. Söderhäll2, J. Kere2, D. Greco4 1Department of Medicine Solna, Translational Immunology Unit, Karolinska Institutet, Stockholm, Sweden 2Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden 3 Dermatology and Venereology Unit, Karolinska University Hospital, Stockholm, Sweden 4 Finnish Institute of Occupational Health, Systems Toxicology Team, Helsinki, Finland P015 CD90+ dermal stromal cells induce an immunosuppressive environment via the induction of regulatory T cells in vitro K. Pfisterer1, K. M. Lipnik2, E. Hofer2, A. Elbe-Bürger1 1Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Laboratory of Cellular and Molecular Immunobiology of the Skin, Medical University of Vienna, Vienna, Austria 2Department of Vascular Biology and Thrombosis Research, Medical University of Vienna, Vienna, Austria P016 Skin inflammation in the absence of adaptive immunity Ö. Uluçkan1, J. Schnabl1, E. F. Wagner1 1BBVA-Foundation–CNIO Cancer Cell Biology Program, Spanish National Cancer Research Centre (CNIO), Madrid, Spain P017 Issues of autoimmunity and autoinflammation in pemphigus, bullous pemphigoid and dermatitis herpetiformis: Comparison of cutaneous pathogeneses J. Gornowicz-Porowska1, M. Bowszyc-Dmochowska1, P. Pietkiewicz1, A. Seraszek-Jaros2, E. Kaczmarek2, M. Dmochowski1 1Department of Dermatology, Poznan University of Medical Sciences, Poznan, Poland 2Department of Bioinformatics and Computational Biology, Poznan University of Medical Sciences, Poznan, Poland P018 Ultraviolet B generates Type 1 Interferon and induces autoantibody-mediated disease in a mouse model of cutaneous lupus C. Sontheimer1,2, K. Elkon1 1University of Washington, Seattle, USA 2Seattle Children‘s Hospital, Seattle, USA Inflammatory Skin Disease Summit 2014 Accepted Abstracts P019 The Use of the 308-nm Excimer Laser for the Treatment of Chronic Hand and Foot Eczema A. Shroff1, D. Malajian2, S. Rose1, D. Bernstein1, G. Singer1, M. Lebwohl1, S. Hadi1, E. Guttman-Yassky1 1Icahn School of Medicine at Mount Sinai, New York, USA 2Columbia University, College of Physicians and Surgeons, New York, USA P020 WITHDRAWN P021 Methylation-induced silencing of the inflammasome adaptor protein ASC in human cutaneous squamous cell carcinoma and its diametric role in inflammation and proliferation K. Meier1, K. Welsch1, F. C. Eberle1, S. K. Drexler2, A. S. Yazdi1 1Department of Dermatology, Eberhard-Karls-University Tuebingen, Germany 2Department of Biochemistry, University of Lausanne, Switzerland P022 The contribution of myeloid cells to Epidermal Growth Factor mediated immune homeostasis in the skin M. Holcmann1, M. Amberg1, B. Lichtenberger2, P.A. Gerber3, M. Sibilia1 1Inst. of Cancer Research; Dept. of Medicine I; Medical University of Vienna, Vienna, Austria 2Centre for Stem Cells and Regenerative Med.; Div. of Genetics; King‘s College, London, Great Britain 3Dept. of Dermatology; University of Düsseldorf, Düsseldorf, Germany P023 Transcriptomic and lipidomic profiling of eicosanoid/docosanoid signalling in affected and non-affected skin of human atopic dermatitis patients J. Mihály1, C. Weise2, A. Barsony1, J. Gericke1*, M. Worm2, R. Rühl1,3 1Department of Biochemistry and Molecular Biology, University of Debrecen, Hungary 2Allergy-Center-Charité, Department of Dermatology and Allergology, Charité – Universitätsmedizin, Berlin, Germany 3Paprika Bioanalytics BT, Debrecen, Hungary *Allergy-Center-Charité, Department of Dermatology and Allergology, Charité – Universitätsmedizin, Berlin, Germany (present address). VIENNA, November 19 – 21, 2014 25 26 Accepted Abstracts P024 Mannan induces ROS-regulated, IL-17A–dependent psoriasis arthritis-like disease in mice I. Khmaladze1, T. Kelkka1, S. Guerard1,2,3, K. Wing1, A. Pizzolla1, A. Saxena1, K. Lundqvist4, M. Holmdahl4, K. Selva Nandakumar1, R. Holmdahl1,3 1Department of Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden 2Turku Doctoral Programme of Biomedical Sciences, Turku, Finland 3Medical Inflammation Research, Medicity Research Lab, University of Turku, Turku, Finland 4 Department of Clinical Dermatology and Venereology, University Hospital, Lund, Sweden P025 The Patient Burden of Atopic Dermatitis: Insights from a Dupilumab Phase 2 Clinical Trial in Adults With Moderate-to-Severe Disease V. Mastey4, E. Simpson1, T. Bieber2, L. Eckert3, R. Wu4, M. Ardeleanu4, N. Graham4, G. Pirozzi5, E.R. Sutherland6 1Oregon Health Sciences University, Portland Oregon, USA ²University of Bonn, Bonn, Germany 3Sanofi, Paris, France 4 Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA 5 Sanofi, Bridgewater, New Jersey, USA 6 Sanofi, Cambridge, Massachusetts, USA P026 Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) A. Menter1, K. Rapp2, G. Krueger3, M. Augustin4, F. Kerdel5, M. Gooderham6, K. Goyal7, S. Fakharzadeh7, W. Langollf7, J.Sermon8, S. Calabro7, D. Pariser9 1Baylor University Medical Center, Dallas, USA 2Probity Medical Research, Waterloo, Canada 3University of Utah, Utah, USA 4 University Clinics of Hamburg, Hamburg, Germany 5 Florida Academic Dermatology Center, Miami, USA 6 SKIN Centre for Dermatology and Probity Medical Research, Peterborough, Canada 7 Janssen Scientific Affairs LLC, Pennsylvania, USA 8 Jannsen-Cilag, Beerse, Belgium 9 Eastern Virginia Medical School and Virginia Clinical Research Inc, Virginia, USA Inflammatory Skin Disease Summit 2014 Accepted Abstracts P027 Malignancies in the psoriasis longitudinal assessment and registry (PSO-LAR) study: Current status of observations D. Fiorentino1, M. Lebwohl2, V. Ho3, R. Langley4, K. Goyal5, S. Fakharzadeh5, S. Calabro5, W. Lanholff5 1Stanford University, Stanford, USA 2Mount Sinai Medical Center, New York, USA 3University of British Columbia, Vancouver, Canada 4 Dalhousie University, Halifax, Nova Scotia, Canada 5 Janssen Scientific Affairs, LLC., Horsham, USA P028 Alterations in immune-modulating analytes in skin wash fluid from healthy elderly subjects K. A. Brogden2, C. L. Fischer2, J. A. Fairley3, N. K. Brogden1 1University of Iowa College of Pharmacy, Department of Pharmaceutical Sciences, Iowa City, USA 2University of Iowa College of Dentistry, Dows Institute for Dental Research, Iowa City, USA 3University of Iowa College of Medicine, Department of Dermatology, Iowa City, USA P029 Persistent inflammation impairs wound healing in a new preclinical porcine ulcer model B. Liehl1, H. Fahrngruber1, V. Gruber1, M. Pillinger1, K. Jahn-Bassler2, W. Bauer2, G. Stingl2, F. Kalthoff1, B. Wolff-Winiski1, E. Kriehuber1 1Novartis Institutes for Biomedical Research, Dept. of Dermatology, Vienna, Austria 2Dept. of Dermatology (DIAID), Medical University of Vienna, Vienna, Austria P030 Whole mount scanning for the quantitative analysis of wound closure in an ex-vivo pig skin model C. Vaculik1, H. Fahrngruber1, V. Gruber1, K. Johnson3, G. Li3, K. Jahn-Bassler2, W. Bauer2, G. Stingl2, E. Kriehuber1, F. Kalthoff1, B. Wolff-Winiski1, B. Liehl1 1Novartis Institutes for Biomedical Research, Dept. of Dermatology, Vienna, Austria 2Dept. of Dermatology (DIAID), Medical University of Vienna, Vienna, Austria 3Novartis Institutes for Biomedical Research, GNF, San Diego, USA VIENNA, November 19 – 21, 2014 27 28 Accepted Abstracts P031 Kappa-opioid receptor agonist WOL071-007 ameliorates ongoing inflammation in mouse models of psoriasis and allergic contact dermatitis M. Soeberdt1, N. Sucker2, A.C. Lüdiger2, U. Knie1, D. Metze2, T.A. Luger2, K. Loser2, C. Abels1 1Dr. August Wolff GmbH & Co. KG Arzneimittel, Bielefeld, Germany 2Department of Dermatology, University of Münster, Münster, Germany P032 CD200R and the regulation of skin immune homeostasis and inflammation A. E. Saunders1 1Manchester Collaborative Centre for Inflammation Research, Inflammation and Repair, Faculty of Human and Medical Sciences, University of Manchester, Manchester, UK P033 Human fibroblast-derived matrix production in 96-well microplates A. P. Winiski1, S. Olt1, S. Wang1, W. Bauer2, K. Jahn2, G. Stingl2, E. Kriehuber1, B. Liehl1, F. Kalthoff1, B. Wolff-Winiski1 1ATI/Dermatology, Novartis Institutes for BioMedical Research, Vienna, Austria 2Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Vienna, Austria P034 Molecular Profiling of Alopecia Areata identifies Th1/Tc1 and Th2/ Tc2 signatures J. Fuentes-Duculan1, M. Suarez-Farinas1, K. Bonifacio1, N. Gulati1, E. Guttman-Yassky1, A. Shemer2, J. G. Krueger1 1Laboratory of Investigative Dermatology, The Rockefeller University, New York, USA 2Department of Dermatology, Tel-Hashomer, Tel Aviv, Israel P035 Filaggrin deficiency leads to Pparα downregulation and impaired 5-Lox signaling S. Blunder1, R. Rühl2, F. Radner3, M. Schmuth1, S. Dubrac1 1Department of Dermatology, Medical University of Innsbruck, Austria 2Department of Biochemistry and Molecular Biology, University of Debrecen, Hungary 3Department of Biochemistry, University of Graz, Austria Inflammatory Skin Disease Summit 2014 Accepted Abstracts P036 Prediction of PASI75 Response in Psoriatic Patients based on gene expression of early time points M. Suarez – Farinas4, C. Correa-da Rosa1, S. Tian2, A. Gottlieb3, J. Krueger4 1Center for Clinical and Translational Science, Rockefeller University, New York, USA 2Division of Clinical Epidemiology, First Hospital of Jilin University, Jilin, China 3Tufts Medical Center, Boston, USA 4 Laboratory for Investigative Dermatology, Rockefeller University, New York, USA P037 Safety and Efficacy of AN2728 Topical Ointment, 2% and 0.5%, in a Phase 2 Dose-Ranging Study of Adolescents with Mild-to-Moderate Atopic Dermatitis L. Stein-Gold1, L. Spelman2, M. Spellman3, M. Hughes4, L. Zane4 1Henry Ford Hospital, Detroit, USA 2Queensland Institute of Dermatology, Queensland, Australia 3Private Practive, San Francisco, USA 4 Anacor Pharmaceuticals Inc., Palo Alto, USA P038 AN2728, A New Boron-Based Topical Anti-Inflammatory Agent, Inhibits Phosphodiesterase 4 (PDE4) Y. Freund1, C. Dong1, C. Virtucio-Frates1, F. Rock1, Y. Mak1, Y. Zhou1, L. Zane1, K. Jarnagin1 1Anacor Pharmaceuticals, Inc., Palo Alto, USA P039 Maximal Use Systemic Exposure (MUSE) Study Evaluating AN2728, A Novel Boron-Based Small Molecule, for the Treatment of Pediatric and Adolescent Subjects with Mild-to-Moderate Atopic Dermatitis L. Kircik1, R. Call2, E. Tschen3, Z. Draelos4, M. Van Syoc5, L. Zane5, A. Hebert6 1DermResearch, PLLC, Louisville, USA 2Clinical Research Partners, LLC, Henrico, USA 3Academic Dermatology Associates, Albuquerque, USA 4 Dermatology Consulting Services, High Point, USA 5 Anacor Pharmaceuticals Inc., Palo Alto, USA 6 Dermatology Clinical Research Unit, University of TX Health Science Center, Houston, USA P040 Sebopsoriasis in HIV-positive patients: Response to topical calcineurin inhibitors T. Tull1, M. Noy1, N. Ioannou1, C. B. Bunker1, N. Morar1 1Chelsea and Westminster NHS Trust, London, UK VIENNA, November 19 – 21, 2014 29 30 Accepted Abstracts P041 A retrospective, hospital-based study of cardiovascular risk factors in patients with psoriasis A. Marak1, R. Chander1 1New Delhi, India P042 Suppression of antigen-specific adaptive immunity by IL-37 via induction of tolerogenic dendritic cells Y.Luo1, X. Cai1, S. Liu1, S. Wang1, C. Nold-Petry2, M. Nold2, P. Bufler3, D. Norris1, C. Dinarello4, M. Fujita1 1Department of Dermatology, University of Colorado AMC, Aurora, USA 2The Ritchie Centre, Monash University, Melbourne, Australia 3Children’s Hospital, Ludwig-Maximilians University, Munich, Germany 4 Department of Medicine, University of Colorado AMC, Aurora, USA P043 RNA-seq of Psoriasis Case-Control Sample Reveals Coexpression of Coding Genes and Long Non-coding RNA Transcripts R. Ahn1, R. Gupta1, K. Lai1, M. Dimon1, J. Pons1, W. Liao1 1University of California, San Francisco, Department of Dermatology, San Francisco, USA P044 Pro-osteoclastogenesis march is induced by cutaneous pro-inflammatory mediators A. Balato1, A. Raimondo1, S. Lembo1, M. Schiattarella1, G. Caiazzo1, R. Di Caprio1, N. Balato1, F. Ayala1 1Department of Dermatology, University of Naples Federico II, Naples, Italy P045 Immune signatures of psoriasis: Comparison of gene expression profiles in psoriasis patients after therapy with biological agents D. Kivelevitch1, M. Sharma1, B. Mansouri1, M. Patel2, C. Ryan2, A. Menter2, G. Obermoser1 1Baylor Insitute for Immunology Research, Dallas, USA 2Menter Research Institute, Dallas, USA P046 CD69 controls CD98-dependent L-tryptophan uptake and AHR-mediated IL-22 secretion in psoriasis D. Cibrián Vera1, M. Laura Saiz1, H. de la Fuente1, R. Sánchez2, I. Jorge Cerrudo2, J. Vazquez2, C. Punzon3, M. Fresno3, P. Martin2, F. Sánchez-Madrid1,2 1Servicio de Inmunología, Hospital de la Princesa, Universidad Autónoma de Madrid, Madrid, Spain, 2Department of Vascular Biology and Inflammation, CNIC, Madrid, Spain 3Departament of Molecular Biology, Centro de Biología Molecular Severo Ochoa, Madrid, Spain Inflammatory Skin Disease Summit 2014 Accepted Abstracts P047 Circadian Rhythm and Skin Inflammation E. Baron1, M. Lam1, A. Suggs1 1Department of Dermatology, University Hospitals, Case Western Reserve University, Cleveland, USA P048 Loss of K-homology type splicing regulatory protein accelerates development of psoriasiform dermatitis in mice I. Ahmad1, E. M. Burns1, W. Min1, C.-F. Chou2, C. A. Elmets1, C.-Y. Chen2, N. Yusuf1 1University of Alabama at Birmingham, Birmingham, USA P049 Insights into stratification of Belimumab responsiveness: self-reactive B cells that are not regulated by BAFF-mediated tolerance N. Nikbakht1, T. Manser2 1Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, USA 2Department of Microbiology and Immunology, Thomas Jefferson University, Philadelphia, USA P050 Efficacy of intravenous immunoglobulins in livedoid vasculopathy: Long term follow up of 11 patients B. Monshi1, C. Posch1, I. Vuic1, A. Sesti1, S. Sobotka1, K. Rappersberger1 1 Department of Dermatology and Venerology,The Rudolfstiftung Hospital, Teaching Hospital of Vienna Medical University, Vienna, Austria P051 Erosive pustular dermatosis (EPDS) of the scalp – therapeutic management with intermittent topical class-3-steroids T. Stockinger1, B. Monshi1, K. Rappersberger1 1Department of Dermatology, Rudolfstiftung Hospital, Vienna, Austria P052 Up-regulation of IL-10 and TGF-β in Flg-deficient skin might prevent chronic skin inflammation V. Moosbrugger-Martinz1, R. Gruber1,2, M. Schmuth1, S. Dubrac1 1Department of Dermatology and Venereology, Innsbruck Medical University, Innsbruck, Austria 2Center for Dermatogenetics, Division of Human Genetics, Innsbruck Medical University, Innsbruck, Austria P053 The role of FoxP3+ regulatory T cells in psoriasiform skin disease K. Adelmann1,2, A.N. Hegazy1, G. Ogg2, F. Powrie1 1Experimental Medicine Division, TGU, NDM, University of Oxford, Oxford, United Kingdom 2MRC Human Immunology Unit, RDM, WIMM, University of Oxford, Oxford, United Kingdom VIENNA, November 19 – 21, 2014 31 32 Accepted Abstracts P054 In vivo analysis of mast cell homeostasis in the skin B. Roediger1,2, P. L. Tong1,2,3, S. S. Tay1,2, R. Jain1,2, W. Weninger1,2,3 1Centenary Institute, Newtown, NSW, Australia 2Discipline of Dermatology, University of Sydney, Camperdown, NSW, Australia 3Department of Dermatology, Royal Prince Alfred Hospital, Camperdown, NSW, Australia P055 Safety and effectiveness of biologic therapy in psoriasis patients with viral hepatitis B or C M. Zarei1, C. Levy2, P. Romanelli1 1Department of Dermatology and Cutaneous Surgery, University of Miami, Miller School of Medicine, Miami, Florida, USA 2Department of Hepatology, University of Miami, Miller School of Medicine, Miami, Florida, USA P056 SLURP-2 may be involved in the pathophysiology of psoriasis H. Tsuji1, H. Takahashi2, T. Kumai1, H. Iizuka2, H. Kobayashi1 1Department of Immunopathology, Asahikawa Medical University, Asahikawa, Japan 2Department of Dermatology, Asahikawa Medical University, Asahikawa, Japan P057 Association of novel regulatory variants in adult, chronic atopic dermatitis T. Pansuriya1, A. Shemer2, K. Gulewicz1, A. Quiggle1, W. Jones1, Z. Goodwin1, E. Guttman-Yassky4, C. de Guzman Strong1 1Washington University School of Medicine, Saint Louis, USA 2Tel-Aviv University, Tel-Aviv, Israel 3Rockefeller University, New York, USA 4 Icahn School of Medicine, New York, USA P058 CCL7 contributes to the TNF-alpha-dependent inflammation of lesional psoriatic skin P.M. Brunner1, E. Glitzner1, B. Reininger1, I. Klein1, G. Stary1, M. Mildner1, P. Uhrin1, M. Sibilia1, G. Stingl1 1Medical University of Vienna, Vienna, Austria P059 Challenging treatment of a patient with progressive severe psoriasis and chronic HBV infection with infliximab C. Luan1, N. Gu1, M. Zhou1, X. Yao1, X. Fan1, M. Chen1 1Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, Jiangsu, China Inflammatory Skin Disease Summit 2014 Accepted Abstracts P060 Upregulation of activating Fc gamma receptors on myeloid antigen-presenting cells in psoriasis C. Bangert1, D. Laimer1, M. Schaschinger1, E. Kriehuber1, T. Kopp2 1Department of Dermatology, DIAID, Vienna, Austria 2Juvenis Medical Center, Vienna, Austria P061 The role of IL-17A in the pathogenesis of Epidermolysis bullosa acquisita M. Wannick1, X. Yu2, Y. Iwakura3, R. Ludwig4, F. Petersen2, C. Hölscher1 1Infection Immunology, Research Center Borstel, Germany 2Biochemical Immunology, Research Center Borstel, Germany 3University of Tokyo, Japan 4 Clinical Dermatology, University Hospital Lübeck, Germany P062 Bullous Pemphigoid: Contribution of IgE Auto-Antibodies to Disease Pathogenesis P. Freire1, N. Reiter1, P. Heil1, G. Stingl1 1Department of Dermatology – Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria P063 Inflammatory effects of common skin microbial species on cultured keratinocytes P. Duckney1, H. K. Wong1, J. Serrano1, T. Oddos1, G. N. Stamatas1 1Johnson & Johnson Santé Beauté France, Issy-les-Moulienaux, France P064 Allergic responses to common sensitizers show lower magnitude and distinct immune polarization in atopic skin D. Malajian1,2, A. Shemer3, J. Correa da Rosa1,4, M. Rozenblit1,5, N. Dhingra1,2, H. Xu1, X. Zheng1, M. Suarez-Farinas1,4, J. G. Krueger1,4, E. Guttman-Yassky1,5 1Laboratory for Investigative Dermatology, Rockefeller University, New York, USA 2Columbia University College of Physicians and Surgeons, New York, USA 3Department of Dermatology, Tel-Hashomer Hospital, Tel-Aviv, Israel 4 Center for Clinical and Translational Science, Rockefeller University, New York, USA 5 Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, USA VIENNA, November 19 – 21, 2014 33 34 Accepted Abstracts P065 The function of miR-146 family in the regulation of proliferation of keratinocytes: implication in psoriasis H. Hermann1, T. Runnel1, A. Aab1, L. Šahmatova2, J Maslovskaja1, B. Rückert3, K. Kingo2, C. A. Akdis3, A. Rebane1 1Institute of Biomedicine and Translational Medicine, University of Tartu, Estonia 2Department of Dermatology and Venereology, University of Tartu, Estonia 3Swiss Institute of Allergy and Asthma Research, University of Zürich, Davos, Switzerland P066 HLA-class II-restricted activation of desmoglein 3-specific CD4+ T cells is required for the formation of pathogenic antibodies in a mouse model of pemphigus vulgaris R. Eming1, T. Hennerici1, J. Bäcklund2, C. Feliciani3, K. Visconti4, S. Willenborg1, J. Wohde1, R. Holmdahl2, G. Sonderstrup4, M. Herti1 1Department of Dermatology and Allergology; Philipps-Universität Marburg, Marburg, Germany 2Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden 3Section of Dermatology, Università degli Studi di Parma, Parma, Italy 4 Department of Microbiology and Immunology, Stanford University, Stanford, USA P067 New potential members of psoriatic transcriptional regulatory network A. Zolotarenko1, S. Bruskin1 1Vavilov Institute of General Genetics, Russian Academy of Sciences, Moscow, Russia P068 Epidermal Protease-activated receptor-2 (PAR2) overexpression causes spontaneous atopic dermatitis-like skin disease: Neuro-Epidermal Communication T. Buhl1, A. Ikoma2, F. Cevikbas2, C. Kempkes2, M. Sulk2, T. Aklyama3, E. Cartens3, P. Elias2, S. R. Coughlin4, M. Steinhoff5 1Dermatology, UMG, Göttingen, Germany 2Dermatology, UCSF, San Francisco, USA 3Center of Neuroscience, UCD, Davis, USA 4 Cardiovascular Research Institute, UCSF, San Francisco, USA 5 Charles Institute for Translational Dermatology, UCD, Dublin, Ireland Inflammatory Skin Disease Summit 2014 Accepted Abstracts P069 Comparative transcriptome analysis in rosacea subtypes display features of the same disease complex without conclusive consecutive evolution M. Steinhoff1, M. Sulk3, V. Schwab3, P. Nowak3, J. Buddenkotte3, F. Cevikbas2, C. Kempkes2, J. Aubert4, J. J. Voegel4, T. Buhl5 1Charles Institute for Translational Dermatology, UCD, Dublin, Ireland 2Dermatology, UCSF, San Francisco, USA 3Dermatology, UKM, Münster, Germany 4 Molecular Dermatology, Galderma R&D, Sophia Antipolis, France 5 Dermatology, UMG, Göttingen, Germany P070 Molecular and morphological Characterization of the inflammatory Infiltrate in Rosacea: new Insights into immune Pathophysiology M. Sulk2, P. Nowak2, J. Buddenkotte2, F. Cevikbas1, C. Kempkes1, J. Aubert3, J.J. Voegel3, M. Ste-inhoff4, T. Buhl5 1Dermatology, UCSF, San Francisco, USA 2Dermatology, UKM, Münster, Germany 3Molecular Dermatology, Galderma R&D, Sophia Antipolis, France 4 Charles Institute for Translational Dermatology, UCD, Dublin, Ireland 5 Dermatology, UMG, Göttingen, Germany P071 NSAIDs not only sensitize melanoma cells to TRAIL-induced apoptosis, but also induce TRAIL expression by innate immune cells M. Vazquez-Strauss1, G. Stingl1 1DIAID, Medical University of Vienna, Vienna, Austria. P072 Molecular IgE sensitization profiles differ between patients with severe and moderate atopic dermatitis I. Mittermann1,4, G. Wikberg2, C. Johansson3, C. Lupinek4, L. Lundeberg2, R. Crameri5, A. Scheynius3 1Christian Doppler Laboratory for the Development of Allergen Chips, Vienna, Austria 2Dermatology and Venereology Unit, Karolinska University Hospital, Stockholm, Sweden 3Translational Immunology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden 4 Division of Immunopathology, Department of Pathophysiology and Allergy Research, Vienna, Austria 5 Swiss Institute of Allergy and Asthma Research (SIAF), University of Zurich, Davos, Switzerland VIENNA, November 19 – 21, 2014 35 36 Accepted Abstracts P073 Treatment with secukinumab rapidly leads to positive proteomic and transcriptional changes in psoriatic skin F. Kolbinger1, G. Bruin1, M. A. Valentin1, T. R. Peters1, E. Khokhlovich1, X. Jiang1, I. Koroleva1, D. Lee1, F. SinneF2,3, T. Pieber2,3, C. Dragatin2, M. Bodenlenz2, C. Loesche1 1Novartis Institutes for BioMedical Research, Basel, Switzerland 2HEALTH – Institute for Biomedicine and Health Sciences, JOANNEUM RESEARCH Forschungsgesellschaft mbH, Graz, Austria 3Division of Endocrinology and Metabolism, Department of Internal Medicine, Medical University of Graz, Graz, Austria P074 Higher activation and cytokine production in circulating CLA+T-cells, suggestive of higher systemic inflammation, in AD vs. psoriasis T. Czarnowicki1, A. Shemer2, J. Gonzales3, J. Krueger1, E. Guttman-Yassky4 1Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA 2The Chaim Sheba Medical Center, Tel-Aviv University, Tel-Hashomer, Tel-Aviv, Israel 3The Translational Technology Core Laboratory (CCTS, The Rockefeller University), New York, USA 4 The Dermatology department at the Icahn School of Medicine at Mount Sinai, New York, USA P075 Effects of Experimental Psoriasis-like Skin Inflammation in Atherosclerosis-prone Mice M. Madsen1, P. R. Hansen2, L. Svensson3, L. B. Nielsen1,4, K. Hartvigsen1, A. E. Pedersen5, J. P. Christensen5, T. X. Pedersen1 1Dept. of Biomedical Sciences, University of Copenhagen, Copenhagen, Denmark 2Dept. of Cardiology, Gentofte University Hospital, Gentofte, Denmark 3LEO Pharma, Ballerup, Denmark 4 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark 5 Dept. of International health, Immunology, and Microbiology, University of Cph, Copenhagen, Denmark Inflammatory Skin Disease Summit 2014 Accepted Abstracts P076 Increased Epidermal Elafin Expression is associated with a Poor Prognosis of Cutaneous Graft-versus-Host Disease M.-C. Brüggen1, P. Petzelbauer2, H. Greinix3, E. Contassot4, D. Jankovic4, L. French4, G. Socié5, W. Rabitsch3, Z. Kuzmina3, P. Kalhs3, R. Knobler6, G. Stingl1, G. Stary1,7 1Department of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria 2Department of Dermatology, Skin & Endothelium Research Division, Medical University of Vienna, Vienna, Austria 3Department of Internal Medicine I, Bone Marrow Transplantation Unit, Medical University of Vienna, Vienna, Austria 4 Department of Dermatology, University Hospital Zurich, Zurich, Switzerland 5 Department of Hematology Transplantation, AP-HP Hospital Saint Louis, Paris, France 6 Department of Dermatology, Division of General Dermatology, Medical University of Vienna, Vienna, Austria 7 Harvard Medical School, Department of Microbiology and Immunobiology, Division of Immunology, Boston MA, USA P077 Molecular Analysis of Intravascular Large B-Cell Lymphoma W. Bauer1, M. Aichelburg1, J. Griss1, H. Kittler2, C. Skrabs3, I. Simonitsch-Klupp4, A. Schiefer4, U. Jäger3, B. Streubel4, G. Stingl1 1Department for Dermatology, Division of Immunology, Allergy and Infectious Diseases, Vienna, Austria 2Department for Dermatology, Division of General Dermatology, Medical University, Vienna, Austria 3Clinical Department for Hematology and Hemostaseology, Department of Medicine I, Vienna, Austria 4 Department of Pathology, Medical University of Vienna, Vienna, Austria P078 A mucosal vaccine against Chlamydia trachomatis generates two synergistic waves of protective memory T cells G. Stary1, A. Olive1, A. F. Radovic-Moreno2,3, D. Gondek1, D. Alvarez1, P. A. Basto2,3, M. Perro1, R. Langer2,3, M. N. Starnbach1, U. H. von Andrian1 1Division of Immunology, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, USA 2Harvard-MIT Division of Health Sciences & Technology, Cambridge, USA 3Department of Chemical Engineering, Massachusetts Institute of Technology, Cambridge, USA VIENNA, November 19 – 21, 2014 37 38 Accepted Abstracts P079 Epigenetic control of IL-23 expression in keratinocytes by TNF and N-WASP H Li1, C. Brakebusch1 1Department of Biomedical Sciences, University of Copenhagen, Ole Maaløes Vej 5, Copenhagen, Denmark P080 Human primary macrophage activation in vitro by wound exudate collected from chronic ulcers F. Kalthoff2, B. Wolff-Winiski2, B. Liehl2, C. Weishaeupl2, E. Foglar2, K. Jahn-Bassler1, W. Bauer1, E. Kriehuber2, G. Stingl1 1Dept. of Dermatology, Division of Immunology, Allergy and Infectious Diseases, Medical University of Vienna, Vienna, Austria 2ATI/Dermatology, Novartis Institutes for BioMedical Research, Vienna, Austria P081 Higher frequencies but impaired suppressive capacity of regulatory T-cells after PUVA in cutaneous T-cell lymphoma P. Vieyra-Garcia1, G. Mayer1, H. Pressl1, E. Reginato1, N. Schweintzger1, I. Bambach1, F. Legat1, A. Hofer1, A. Gruber-Wackernagel1, L. Cerroni1, R. Fink-Puches1, P. Wolf1 1Department of Dermatology and Venereology, Medical University of Graz, Austria P082 Epicutaneous application of recombinant Bet v 1 and Bet v 1 derivatives induces allergen-specific IgG and T cell responses R. Campana1, K. Moritz2, A. Neubauer3, H. Huber3, R. Henning 3, K. Blatt4, G. Hoermann5, T. M. Brodie6, A. Kaider7, P. Valent4, F. Sallusto6, S. Wöhrl2, R. Valenta1 1Division of Immunopathology, Department of Pathophysiology, Center of Physiology and Patho-physiology, Vienna General Hospital (AKH), Medical University of Vienna, Austria 2Division of Immunology, Allergy and Infectious Diseases, Department of Dermatology, Vienna General Hospital (AKH), Medical University of Vienna, Austria 3Biomay AG, Vienna, Austria 4 Division of Hematology and Hemostaseology, Department of Internal Medicine I, Vienna General Hospital (AKH), Medical University of Vienna, Austria 5 Department of Laboratory Medicine, Vienna General Hospital (AKH), Medical University of Vienna, Austria 6 Cellular Immunology Laboratory, Institute for Research in Biomedicine, Bellinzona, Switzerland 7 Center for Medical Statistics, Informatics and Intelligent Systems, Section for Clinical Biometrics, Medical University of Vienna, Austria Inflammatory Skin Disease Summit 2014 Accepted Abstracts P083 RNA-Seq profiling increases the atopic dermatitis transcriptome and identifies novel pro-inflammatory genes with potential therapeutic implications M. Suarez-Fariñas1, B. Ungar2,1, M. Rozenblit2,1, H. Mitsui1, H. Xu2, J. G. Krueger1, E. Guttman-Yassky2,1 1The Laboratory for Investigative Dermatology, The Rockefeller University, New York NY, USA 2Department of Dermatology and Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, NY P084 Identification of Novel Immune and Barrier Genes in Atopic Dermatitis by Laser Capture Micro-dissection H. Esaki1,2, D. A. Ewald1,3,4, B. Ungar1,2, M. Rozenblit1,2, X. Zheng1, H. Xu1, Y. D. Estrada1,2, X. Peng1,2, H. Mitsui1, T. Litman3, M. Suárez-Fariñas1, J. G. Krueger1, E.Guttman-Yassky1,2 1The Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA 2Department of Dermatology and Laboratory for Inflammatory Skin Diseases, Icahn School of Medicine at Mount Sinai, New York, USA 3Molecular Biomedicine, LEO Pharma, Ballerup, Denmark 4 Center for Microbial Biotechnology, DTU Systems Biology, Technical University of Denmark, Lyngby, Denmark P085 A retrospective single-center cohort analysis of 118 patients with moderate to severe hidradenitis suppurativa L. Oberleitner1, P. Viznerova1, E. Riedl1 1Department of Dermatology, Medical University of Vienna, Vienna, Austria P086 Correlation of a novel histopathologic Psoriasis score with clinical disease scores in plaque-type psoriasis E. Riedl1, H. Kittler1, T. Kopp1, S. Khalilieh2 1Department of Dermatology, Medical University of Vienna, Vienna, Austria, 2Merck & Co., Inc., Whitehouse Station NJ, USA P087 Personality traits impact the quality of life assessment in patients with psoriasis A. Wesinger1, P. Viznerova1, E. Lehner-Baumgartner2, H. Kittler1, H. Pehamberger1, E. Riedl1 1Department of Dermatology, Division of General Dermatology, Medical University of Vienna, Vienna, Austria 2Department of Clinical Psychology, Vienna General Hospital, Vienna, Austria VIENNA, November 19 – 21, 2014 39 Accepted Abstracts Prescribing Information see page 42 40 *Enbrel is indicated for moderate-to-severe plaque psoriasis. References: 1. Nast A et al. JDDG. 2012;10(Suppl 2):S1-S95. 2. Menter A, Gottlieb A et al. J Am Acad Dermatol. 2008;58:826-850. 3. Watson T & de Bruin D. Indo-Pacific Journal of Phenomenology. 2006;6(2):1-12. 4. Gottlieb AB. Nature Rev Drug Discov. 2005;4(1):19-34. EU-ENB41014. Date of preparation: October 2014. ENB-130-14/1/10.10.2014. Inflammatory Skin Disease Summit 2014 Accepted Abstracts Help your psoriasis patients follow their unique and changing path in life* VIENNA, November 19 – 21, 2014 41 42 Commercial Exhibition/Sponsorship Commercial Exhibition/Sponsorship EXHIBITION HOURS Wednesday, November 19, 2014 Thursday, November 20, 2014 Friday, November 21, 2014 15:00 – 21:00 09:00 – 21:00 08:00 – 11:00 LIST OF EXHIBITORS Bayer Celgene Eli Lilly Galderma Janssen Medimmune Merck Novartis Stiefel/GSK Ins Enbrel 21.10.14 11:28 Seite 3 Prescribing Information page 40-41 Enbrel 25 mg powder and solvent for solution for injection, Enbrel 25 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled pen, Enbrel 10 mg powder and solvent for solution for injection for paediatric use. Qualitative and quantitative composition: Each vial contains 10/25 mg of etanercept, each pre-filled syringe contains 25 mg/ 50 mg of etanercept, each pre-filled pen contains 50 mg of etanercept. List of excipients: Enbrel 25 mg powder and solvent for solution for injection & Enbrel 10 mg powder and solvent for solution for injection for paediatric use: Powder: Mannitol (E421), sucrose, trometamol. Solvent: Water for injections. Enbrel 25 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled pen: Sucrose, sodium chloride, L-Arginine hydrochloride, sodium phosphate monobasic dehydrate, sodium phosphate dibasic dehydrate, water for injections. Therapeutic indications: Enbrel 25 mg powder and solvent for solution for injection, Enbrel 25 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled syringe, Enbrel 50 mg solution for injection in pre-filled pen: Rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, axial spondyloarthritis: Ankylosing spondylitis (AS) & non-radiographic axial Spondyloarthritis, plaque psoriasis, paediatric plaque psoriasis. Enbrel 10 mg powder and solvent for solution for injection for paediatric use: Juvenile idiopathic arthritis, paediatric plaque psoriasis. (For details please refer to the Summary of Product Characteristics). Contraindications: Hypersensitivity to the active substance or to any of the excipients. Sepsis or risk of sepsis. Treatment with Enbrel should not be initiated in patients with active infections, including chronic or localised infections. Pharmacotherapeutic group: Immunosuppressants, Tumour Necrosis Factor alpha (TNF- ) inhibitors, ATC code: L04AB01. Marketing authorization holder: Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ, United Kingdom. Date of revision of the text: 07/2014. General classification for supply: Subject to medical prescription, available in pharmacies only, non-renewable prescription. For details of special warnings and precautions for use, interaction with other medicinal products and other forms of interaction, pregnancy and lactation and undesirable effects please refer to the published Summary of Product Characteristics. Inflammatory Skin Disease Summit 2014 Commercial Exhibition/Sponsorship Platinum Sponsors Gold Sponsors Silver Sponsors Regular Sponsors VIENNA, November 19 – 21, 2014 43 44 Industry-Supported Sessions Industry-Supported Sessions THURSDAY, NOVEMBER 20, 2014 12:00 – 14:00 Regeneron and Sanofi Satellite Symposium Atopic Dermatitis: New Understandings of Pathology, New Advances in Therapy 12:00 – 12:30 Registration and Lunch 12:30 – 12:40 Chairman’s Introductory Remarks Emma Guttman-Yassky (New York City, NY) 12:40 – 13:00 Assessing the Current Treatment Landscape in Atopic Dermatitis: Our Patients’ Needs Are Not Being Met Georg Stingl (Vienna, AT) 13:00 – 13:20 Loss of Function Mutations in the FLG Gene, Skin Barrier Dysfunction and Allergic Sensitization Matthias Schmuth (Innsbruck, AT) 13:20 – 13:40 From Bench to Bedside: Translating New Understandings of Pathology Into Therapy Emma Guttman-Yassky (New York City, NY) 13:40 – 14:00 Question and Answer Session THURSDAY, NOVEMBER 20, 2014 15:30 – 17:00 Pfizer Satellite Symposium 15.30 – 15.35 Welcome and introduction Robert Strohal (Feldkirch, AT) 15.35 – 16:05 The need for a patient-centered approach in psoriasis Robert Strohal (Feldkirch, AT) 16:05 – 16:35 Maintaining long-term response in psoriasis: Role of immunogenicity Manuel Carrascosa (Barcelona, ES) 16:35 – 17:00 Using our wealth of experience to shape the future of patient-care Frank Nestle (London, UK) Inflammatory Skin Disease Summit 2014 Industry-Supported Sessions Ins. Xolair 21.10.14 11:22 Seite 2 Prescribing Information page 4 BEZEICHNUNG DES ARZNEIMITTELS: Xolair 75 mg Injektionslösung – Xolair 150 mg Injektionslösung – Omalizumab QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: Xolair 75mg Injektionslösung: Jede Fertigspritze mit 0,5 ml Lösung enthält 75 mg Omalizumab*. Xolair 150 mg Injektionslösung: Jede Fertigspritze mit 1 ml Lösung enthält 150 mg Omalizumab. *Omalizumab ist ein humanisierter monoklonaler Antikörper, der durch rekombinante DNA-Technologie in einer Säugetier-Zelllinie aus dem Ovar des chinesischen Hamsters (CHO) hergestellt wird. Vollständige Auflistung der sonstigen Bestandteile, siehe Abschnitt 6.1. der Fachinformation. Liste der sonstigen Bestandteile: L-Argininhydrochlorid, L-Histidinhydrochlorid, L-Histidin, Polysorbat 20, Wasser für Injektionszwecke. Anwendungsgebiete: Xolair 75 mg Injektionslösung: Xolair wird angewendet bei Erwachsenen, Jugendlichen und Kindern (6 bis <12 Jahre). Die Behandlung mit Xolair sollte nur bei Patienten in Betracht gezogen werden, bei denen von einem IgE-(Immunglobulin E-)vermittelten Asthma ausgegangen werden kann (siehe Abschnitt 4.2 der Fachinformation). Erwachsene und Jugendliche (ab 12 Jahren): Xolair wird als Zusatztherapie zur verbesserten Asthmakontrolle bei Patienten mit schwerem persistierendem allergischem Asthma angewendet, die einen positiven Hauttest oder In-vitro-Reaktivität gegen ein ganzjährig auftretendes Aeroallergen zeigen und sowohl eine reduzierte Lungenfunktion (FEV1 <80 %) haben als auch unter häufigen Symptomen während des Tages oder nächtlichem Erwachen leiden und trotz täglicher Therapie mit hoch dosierten inhalativen Kortikosteroiden und einem lang wirkenden inhalativen Beta2Agonisten mehrfach dokumentierte, schwere Asthma-Exazerbationen hatten. Kinder (6 bis <12 Jahre): Xolair wird als Zusatztherapie zur verbesserten Asthmakontrolle bei Patienten mit schwerem persistierendem allergischem Asthma angewendet, die einen positiven Hauttest oder in vitro Reaktivität gegen ein ganzjährig auftretendes Aeroallergen zeigen und unter häufigen Symptomen während des Tages oder nächtlichem Erwachen leiden und trotz täglicher Therapie mit hoch dosierten inhalativen Kortikosteroiden und einem lang wirkenden inhalativen Beta2-Agonisten mehrfach dokumentierte, schwere AsthmaExazerbationen hatten. Xolair 150 mg Injektionslösung: Allergisches Asthma: Xolair wird angewendet bei Erwachsenen, Jugendlichen und Kindern (6 bis <12 Jahre). Die Behandlung mit Xolair sollte nur bei Patienten in Betracht gezogen werden, bei denen von einem IgE-(Immunglobulin E-)vermittelten Asthma ausgegangen werden kann (siehe Abschnitt 4.2). Erwachsene und Jugendliche (ab 12 Jahren): Xolair wird als Zusatztherapie zur verbesserten Asthmakontrolle bei Patienten mit schwerem persistierendem allergischem Asthma angewendet, die einen positiven Hauttest oder In-vitro-Reaktivität gegen ein ganzjährig auftretendes Aeroallergen zeigen und sowohl eine reduzierte Lungenfunktion (FEV1 <80 %) haben als auch unter häufigen Symptomen während des Tages oder nächtlichem Erwachen leiden und trotz täglicher Therapie mit hoch dosierten inhalativen Kortikosteroiden und einem lang wirkenden inhalativen Beta2-Agonisten mehrfach dokumentierte, schwere AsthmaExazerbationen hatten. Kinder (6 bis <12 Jahre): Xolair wird als Zusatztherapie zur verbesserten Asthmakontrolle bei Patienten mit schwerem persistierendem allergischem Asthma angewendet, die einen positiven Hauttest oder in vitro Reaktivität gegen ein ganzjährig auftretendes Aeroallergen zeigen und unter häufigen Symptomen während des Tages oder nächtlichem Erwachen leiden und trotz täglicher Therapie mit hoch dosierten inhalativen Kortikosteroiden und einem lang wirkenden inhalativen Beta2Agonisten mehrfach dokumentierte, schwere Asthma-Exazerbationen hatten. Chronische spontane Urtikaria (csU): Xolair wird als Zusatztherapie für die Behandlung der chronischen spontanen Urtikaria bei Erwachsenen und Jugendlichen (ab 12 Jahren) mit unzureichendem Ansprechen auf eine Behandlung mit H1-Antihistaminika angewendet. Gegenanzeigen: Überempfindlichkeit gegen den Wirkstoff oder einen der sonstigen Bestandteile. Pharmakotherapeutische Gruppe: Mittel bei obstruktiven Atemwegserkrankungen, andere Mittel bei obstruktiven Atemwegserkrankungen zur systemischen Anwendung, ATC-Code: R03DX05. INHABER DER ZULASSUNG: Novartis Europharm Limited, Wimblehurst Road, Horsham, West Sussex, RH12 5AB, Vereinigtes Königreich. Verschreibungspflicht/Apothekenpflicht: NR, apothekenpflichtig. Informationen betreffend Warnhinweise und Vorsichtsmaßnahmen für die Anwendung, Wechselwirkung mit anderen Mitteln, Nebenwirkungen und Gewöhnungseffekte sind den veröffentlichten Fachinformationen zu entnehmen. Version: 02/2014 VIENNA, November 19 – 21, 2014 45 46 Industry-Supported Sessions Inflammatory Skin Disease Summit 2014